RCT | Iron chelation with Deferiprone fails to improve outcomes in Parkinson’s Disease.

Trial of Deferiprone in Parkinson’s Disease – New England Journal of Medicine (link to abstract – $ for full-text)

Commentary: Deferiprone Not Beneficial for Newly Diagnosed Parkinson Disease – HealthDay

Commentary on Twitter

Iron deposition in the substantia nigra has been implicated in Parkinson’s disease. Chelation with deferiprone reduced brain iron content but led to worse scores on scales of the movement disorder at 36 weeks. https://t.co/aXYCzAt2JM pic.twitter.com/Lw07VK5ZJX

— NEJM (@NEJM) December 3, 2022